株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:非ホドキンリンパ腫(NHL)の疫学的予測

EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 301409
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
EpiCast Report:非ホドキンリンパ腫(NHL)の疫学的予測 EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2024
出版日: 2016年01月01日 ページ情報: 英文 67 Pages
概要

非ホドキンリンパ腫(NHL)とは、リンパ系で発達する癌の一種で、悪性の白血球の増加が制御不能となり、それが人体の免疫系統に悪影響をもたらし、人体が感染症やその他の疾患に対処できなくなってしまう、という疾患です。NHLはB細胞・T細胞・ナチュラルキラーの3つの種類に区分され、先進国ではB細胞が最も一般的となっています。数多くの研究結果にも関わらず、NHLは現在でもほとんど治療不可能であり、またその原因も分かっていません。世界の主要6ヶ国におけるB細胞NHLの患者数は、2013年の89,455人から、2023年には111,366人にまで増加する(その間の年平均成長率(CAGR)は2.45%)と予想されています。米国が最大の患者数を抱え(2023年には56,033人)、次いでドイツ(同17,176人)、英国(同12,548人)の順となっています。

当レポートでは、世界の主要6ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国)における非ホドキンリンパ腫(NHL)の発症状況や今後の見通しについて分析し、疾患の特徴(リスク要因や主な共存症など)や世界各国での動向、現在の有病者の発症状況、今後10年間の発症・有病件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概要
  • 近日刊行の関連調査

第3章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界的な傾向
    • 米国
    • 欧州5ヶ国
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
    • 年齢調整済みの罹患率
  • B細胞NHLの疫学的予測(今後11年間分)
    • 濾胞性リンパ腫
    • 辺縁帯リンパ腫
    • びまん性大細胞型B細胞リンパ腫(DLBCL)
    • マントル細胞リンパ腫
  • 議論
    • 疫学的な予測に関する結論
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER113-15

Non-Hodgkin's Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body's immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body's inability to fight infections and other diseases. NHL is characterized into three types - B-cell, T-cell, and natural killer lymphocyte lymphomas. This epidemiological analysis focuses specifically on four subtypes of B-cell NHL: follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma. NHL is more common in men than in women, in white men and women compared with black men and women, and the incidence exponentially increases with age.

GlobalData epidemiologists forecast an increase in the incident cases of the four B-cell NHL in the 7MM, from 104,854 incident cases in 2014 to 129,179 incident cases in 2024, with an annual growth rate (AGR) of 2.32%. Throughout the forecast period, the US will have the highest number of incident cases of B-cell NHL, as well as 36% growth during the forecast period, ending with 57,724 incident cases in 2024. Additionally, each of the 7MM will see an increase in incident cases over the 10-year forecast period.

For this analysis, GlobalData epidemiologists utilized peer-reviewed journals and country-specific disease databases to construct the 10-year epidemiological forecast for the incident cases of follicular lymphoma, marginal zone lymphoma, DLBCL, and mantle cell lymphoma in the 7MM. A major strength of GlobalData's epidemiological analysis is the exclusive use of country-specific sources, allowing for a meaningful comparison of the epidemiological characteristics of B-cell NHL in the 7MM. In addition, this forecast provides detailed segmentation of the B-cell NHL for each country by age, sex, and B-cell NHL subtype, thereby providing a comprehensive view of B-cell NHL in the seven markets. Furthermore, GlobalData epidemiologists constructed and analyzed each B-cell NHL subtype individually, which facilitated an in-depth understanding of B-cell NHL in the 7MM.

Scope

  • The Non-Hodgkin's Lymphoma (NHL) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for NHL in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the incident cases of NHL segmented by sex, age (in five-year increments beginning at 30 years and ending at =85 years), and subtypes in these markets.
  • The NHL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The NHL EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global NHL market.
  • Quantify patient populations in the global NHL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for NHL therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for B-Cell NHL (2014-2024)
    • 3.5.1. Follicular Lymphoma
    • 3.5.2. Marginal Zone Lymphoma
    • 3.5.3. DLBCL
    • 3.5.4. Mantle Cell Lymphoma
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for NHL
  • Table 2: US, Age- and Sex-Specific Incidence of B-Cell NHL during 2001-2010
  • Table 3: 7MM, Sources of B-Cell NHL Incidence Data
  • Table 4: 7MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 5: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N (Row %), 2014
  • Table 6: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N (Row %), 2014
  • Table 7: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 8: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N (Row %), 2014
  • Table 9: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N (Row %), 2014
  • Table 10: 7MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 11: 7MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N (Row %), 2014
  • Table 12: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N (Row %), 2014
  • Table 13: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 14: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N (Row %), 2014
  • Table 15: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N (Row %), 2014

List of Figures

  • Figure 1: 7MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 2: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014
  • Figure 3: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N, 2014
  • Figure 4: 7MM, Age-Standardized Incidence of Follicular Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
  • Figure 5: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 6: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014
  • Figure 7: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N, 2014
  • Figure 8: 7MM, Age-Standardized Incidence of Marginal Zone Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
  • Figure 9: 7MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 10: 7MM, Age-Specific Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2014
  • Figure 11: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N, 2014
  • Figure 12: 7MM, Age-Standardized Incidence of DLBCL (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
  • Figure 13: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 14: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N, 2014
  • Figure 15: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N, 2014
  • Figure 16: 7MM, Age-Standardized Incidence of Mantle Cell Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
Back to Top